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Previous studies on the impact of hexavalent chromium [Cr(VI)] on mammalian cell energetics
revealed alterations suggestive of a shift to a more fermentative metabolism. Aiming at a more
deﬁned understanding of the metabolic effects of Cr(VI) and of their molecular basis, we assessed
the impact of a mild Cr(VI) exposure on critical bioenergetic parameters (lactate production, oxygen
consumption and intracellular ATP levels). Cells derived from normal human bronchial epithelium
(BEAS-2B cell line), the main in vivo target of Cr(VI) carcinogenicity, were subjected for 48 h to 1 lM
Cr(VI). We could conﬁrm a shift to a more fermentative metabolism, resulting from the simulta-
neous inhibition of respiration and stimulation of glycolysis. This shift was accompanied by a
decrease in the protein levels of the catalytic subunit (subunit b) of the mitochondrial H+-ATP syn-
thase (b-F1-ATPase) and a concomitant marked increase in those of glyceraldehyde-3-phosphate
dehydrogenase (GAPDH). The corresponding alteration in the b-F1-ATPase/GAPDH protein ratio
(viewed as a bioenergetic signature) upon Cr(VI) exposure was in agreement with the observed
attenuation of cellular respiration and enhancement of glycolytic ﬂux. Altogether, these results con-
stitute a novel ﬁnding in terms of the molecular mechanisms of Cr(VI) effects.
 2014 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Heavy exposure to Cr(VI) compounds, extensively used in
chemical, metallurgical and refractory industries, has been ﬁrmlyassociated with an increased risk of lung cancer and of a rare can-
cer of the sinonasal cavity [23,37]. The general population may also
be at risk, as these occupational carcinogens are now widespread
in the environment, due to landﬁll disposal of Cr(VI)-containing
waste, automobile emissions and fuel combustion, amongst other
causes [50]. Similar to all other cancers, Cr(VI)-induced lung cancer
is likely associated with dynamic changes in the genome. Accord-
ingly, much research effort has been devoted to the study of Cr(VI)
genotoxicity. Interestingly, Cr(VI) itself does not react extensively
with DNA, but its intracellular reduction generates a variety of
DNA damaging species. Amongst these species are trivalent chro-
mium [Cr(III)], the ﬁnal product of this reduction [54], and strong
oxidants such as tetravalent chromium [Cr(IV)], pentavalent chro-
mium [Cr(V)] and, possibly, reactive oxygen species (ROS) [33].
Altogether, these reactive species induce a wide spectrum of
potentially mutagenic DNA lesions (adducts, strand breaks,
oxidized bases, abasic sites and crosslinks) and other genetic
defects [49,50]. Signiﬁcantly, in the TP53 gene, which encodes
p53, a critical ‘‘guardian of the genome’’ [27], Cr(III) binds preferen-
tially to -NGG- sequences [4]. As these are the sequences of three
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that Cr(III)-DNA adducts might induce mutations in TP53 that, in
turn, will facilitate the accumulation, along hundreds of genera-
tions, of further mutations in this and other genes needed for
uncontrolled cellular proliferation.
Notwithstanding the fundamental role that mutations in estab-
lished cancer genes play in carcinogenesis, it is becoming increas-
ingly clear that defects in the mechanisms that govern normal cell
proliferation, cell death and tissue homeostasis do not lead, per se,
to tumor formation. Incipient cancer cells must also rewire their
metabolism in order to meet the augmented demands for energy,
reducing power and biosynthetic precursors associated with
uncontrolled proliferation [20]. To this day, the best-characterized
metabolic phenotype of cancer cells is a strong reliance on lactic
fermentation for energy generation, despite the presence of an
adequate oxygen supply [51]. First unveiled by Otto Warburg in
the 1920s, this shift to ‘‘aerobic glycolysis’’ came to be known as
the Warburg effect.
The exact molecular basis of the Warburg effect remains essen-
tially unknown, but it has been reported that, in several common
human cancers, it correlates closely with decreased levels of the
mitochondrial marker b-F1-ATPase, compared to paired normal tis-
sues [9,11,12,21,25], which suggests a loss of mitochondrial poten-
tial for energy generation. On the contrary, the same cancers
exhibited frequently augmented levels of the glycolytic marker
GAPDH [2,12,24,25,48], pointing to an increased glycolytic compe-
tence. Altogether, these changes translate into a lower b-F1-ATP-
ase/GAPDH protein ratio, which has been deﬁned a bioenergetic
signature [43]. Very importantly, it was found that the in vivo glu-
cose uptake of lung carcinomas correlated inversely with this ratio
[29] and it was shown that, for some of these cancers, this bioen-
ergetic signature might be used as a marker for cancer progression
[11,12,24,28]. It was also suggested that H+-ATP synthase down-
regulation could be used as a predictive marker of tumor response
to chemotherapy [46].
Impact of Cr(VI) exposure in mammalian cell bioenergetics
remains largely unexplored. There is already evidence that it inhib-
its respiration and negatively affects the cellular energy status, and
there are also some reports of changes in nutrient uptake and in
aerobic glycolysis [1], but the establishment of Cr(VI)-induced
metabolic trends and a clear understanding of their effective role
in Cr(VI)-induced carcinogenesis requires much more additional
work. In this study, we assessed the impact of a short-term (48
h) exposure to a low Cr(VI) concentration (1 lM) on the bioener-
getic phenotype of human epithelial bronchial cells. Aiming at an
elucidation of the underlying mechanisms of the changes that were
observed, we also assessed the effects of this exposure on the cells’
bioenergetic signature, intracellular ATP levels and levels of oxida-
tive stress.
2. Materials and methods
2.1. Cell culture
BEAS-2B cells, obtained from the European Collection of Animal
Cell Cultures (Salisbury, UK; ECCAC no. 95102433) were used
throughout this study. These cells were grown in a serum-free
medium (Gibco LHC-9 medium, from Invitrogen). Cultures were
established in tissue culture-grade ﬂasks or multiwell plates pre-
coated with gelatine (from bovine skin, type B, Sigma–Aldrich)
and maintained at 37 C in a humidiﬁed atmosphere of 95% air/
5% CO2. Cells were seeded at 4000 cells/cm2 and subcultured at
70–80% conﬂuence (typically, 3–4 days after seeding). Under these
culture conditions, the stationary phase of growth was never
reached. Cultures used in the different experiments were in pas-
sages 11–19.2.2. Cr(VI) exposures
In all experiments, cells were allowed to attach to the substrate
for 24 h prior to the addition of Cr(VI). Final concentrations of
Cr(VI), ranging between 0.1 and 2.0 lM, were achieved through
addition to the growth medium of adequate volumes of ﬁlter-ster-
ilized 5 or 50 lM K2Cr2O7 (Sigma–Aldrich) aqueous solutions. Con-
trol cultures, established and processed in parallel, received an
equivalent amount of the vehicle (water).
2.3. Colony formation assay
Clonogenic potentials were determined using the colony forma-
tion assay, as described by Franken and collaborators [16]. Brieﬂy,
cells were seeded into 6-well plates (300 cells/well) and subjected
to different Cr(VI) exposures. At least two cultures were prepared
for each condition. Nine or ten days after seeding, colonies were
ﬁxed and stained with a solution containing 6.0% (v/v) glutaralde-
hyde (Sigma–Aldrich) and 0.5% (w/v) crystal violet (Sigma–
Aldrich). Colonies were counted by direct observation, scoring all
colonies that stained purple. For the calculation of plating efﬁcien-
cies, deﬁned as the ratio, in percentage, of number of colonies
formed to number of cells seeded, the number of colonies in the
replicate cultures was averaged.
2.4. Determination of protein contents
In those experiments where results were standardized to pro-
tein content, trypsinized cultures were washed with phosphate-
buffered saline (PBS), resuspended in an adequate volume of lysis
buffer [10 mM tris base (Sigma–Aldrich), pH 7.5; 130 mM NaCl;
1% (v/v) Triton X-100 (Merck); ethylenediaminetetracetic acid
(EDTA)-free protease inhibitor cocktail (1 tablet per 0.95 mL buf-
fer; Roche, Cat. No. 11 836 170 001)] and centrifuged at 11,000g
and 4 C for 15 min. Supernatants were transferred to new centri-
fuge tubes and their protein contents were determined by the
Bradford method [6], using the Bio-Rad protein assay dye reagent
concentrate (Bio-Rad) and bovine serum albumin as a standard.
2.5. Determination of oxygen consumption rates
Oxygen consumption rates (OCRs) were measured using the
Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience).
For these determinations, cells were seeded into the wells of a XF
24-well cell culture microplate (20,000 cells/well in 250 lL of
medium). Eight replicate cultures were used for each condition.
At the end of the Cr(VI) exposure, spent mediumwas replaced with
700 lL of fresh, Cr(VI)-free medium and cells were incubated at
37 C for 60 min to allow for media temperature and pH to reach
equilibrium. After obtaining the basal OCR, oligomycin (Sigma–
Aldrich), 2,4-dinitrophenol (2,4-DNP, Sigma–Aldrich), rotenone
(Sigma–Aldrich) and antimycin (Sigma–Aldrich) were sequentially
added to each well (in 50 lL of LHC-9 medium) to ﬁnal concentra-
tions of 6 lM, 750 lM, 1 lM and 1 lM, respectively. OCRs under
these different conditions were measured between additions. OCRs
were expressed in pmol O2/min/lg protein.
2.6. Determination of lactate production
For these determinations, cells were seeded into 6-well plates
(100,000 cells/well). Tetraplicate cultures were used for each con-
dition. At the end of the Cr(VI) exposure, spent medium was
replaced with fresh, Cr(VI)-free medium, with or without 6 lM oli-
gomycin or 750 lM 2,4-DNP. Incubations with oligomycin lasted
4 h and those with 2,4-DNP 1 h. After the incubations, the decrease
in lactate levels in the growth medium over a 4 h period was
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collected at times 0 and 4 h and treated with 6% (v/v) perchloric
acid (Merck) to stop lactate dehydrogenase enzymatic activity.
After 30 min on ice, the samples were centrifuged, for 5 min, at
11,000g and 4 C. Supernatants, kept on ice, were neutralized with
20% (w/v) KOH (Merck) and centrifuged at 11,000g and 4 C for
5 min to sediment the KClO4 salt. Lactate levels in the clear super-
natants were determined using a lactate dehydrogenase (LDH)-
based enzymatic assay. For standardization purposes, protein
contents were determined as described in Section 2.4. The rate of
lactate production was expressed in nmol lactate/h/lg protein.
2.7. Determination of intracellular ATP levels
Intracellular levels of ATP were determined enzymatically using
the ATP Bioluminescence Assay Kit HS II (Roche), which is based on
the ATP dependency of the light emitting oxidation of luciferin,
catalyzed by luciferase [13]. Cultures were prepared in 6-well
plates (seeding density of either 100,000 or 150,000 cells/well),
using triplicate cultures for each condition. At the end of the Cr(VI)
exposure, spent medium was replaced with fresh, Cr(VI)-free med-
ium with or without 6 lM oligomycin, 750 lM 2,4-DNP or 100 lM
2-deoxyglucose (2-DG, Sigma–Aldrich). After a one-hour incuba-
tion, cells were collected by trypsinization and disrupted by addi-
tion of 400 lL of boiling ATP lysis buffer [100 mM tris base, pH
7.75; 4 mM EDTA]. After 2 min at 95 C, extracts were centrifuged
at 11,000g for 15 min. ATP solutions with concentrations ranging
from 1.6  10–9 to 1.6  10–6 M were used as standards. Lumines-
cence was measured using a FLUOstar OPTIMA plate luminometer
(BMG Labtech). Intracellular ATP levels were expressed in nmol
ATP/106 cells.
2.8. Western blot analysis
Proteins from cellular extracts were fractionated by SDS-PAGE.
The fractionated proteins were transferred to a polyvinylidene
ﬂuoride (PVDF) membrane for immunoblot analysis. Mouse pri-
mary monoclonal antibodies were used for Hsp60 and GAPDH
detection (Enzo Life Sciences and Abcam, respectively), whereas a
polyclonal rabbit antibody was used for b-F1-ATPase detection
[12]. Peroxidase-conjugated anti-mouse or anti-rabbit IgGs (Nordic
Immunology) were used as secondary antibodies. The dilutions
used were 1:20,000 for the primary antibodies and 1:5000 for
the secondary antibodies. The blots were developed using the
Novex ECL chemiluminescent reagent kit (Invitrogen). Expression
levels in control and Cr(VI)-exposed samples were normalized rel-
ative to those of the same proteins found in HCT116 cells extracted
in parallel and assayed in the same gels and expressed relative to
the mean value of unexposed cells.
2.9. Assessment of oxidative stress
Oxidative stress was assessed in cultures established in 6-well
plates (100,000 cells/well). Tetraplicate cultures were used for
each condition. After Cr(VI) exposure, control and Cr(VI)-exposed
cultures were incubated for 1 h in fresh, Cr(VI)-free medium with
or without 6 lM oligomycin. Cell pellets, obtained by trypsiniza-
tion, were resuspended in 300 lL of a 5 lM 20,70-dichlorodihydro-
ﬂuorescein diacetate (DCFH-DA) solution (Invitrogen) and placed
at 37 C for 30 min (protected from light). The cellular suspensions
were then centrifuged at 1500 rpm for 5 min and the resulting pel-
lets were dispersed into 200 lL of a buffer containing 1.0% (v/v)
fetal bovine serum (Gibco) and 0.1% (w/v) sodium azide in PBS.
Propidium iodide (PI; 1 lL; Sigma–Aldrich) was added to each
sample to detect dead cells. The ﬂuorescence emitted by 20,
70-dichloroﬂuorescein (DCF) and PI was detected by ﬂowcytometry using a FACSCalibur System (BD Biosciences). The ﬂow
cytometer was equipped with two lasers, 488 nm (Blue) and
663 nm (Red), and four ﬂuorescence detectors, FL1 (Blue, 530/
30 nm), FL2 (Blue, 585/42 nm), FL3 (Blue, 670 nm LP) and FL4
(Red, 660/14 nm). DCF and PI emissions were collected through
the FL1 and FL3 channels, respectively. Acquisition and analysis
of gates were set using BD CellQuest Pro software. Brieﬂy, live cells
were identiﬁed based on PI dye exclusion and intact cells based on
the FSC-H and SSC-H parameters. Then, DCF-positive cells were
identiﬁed. At least 10,000 events were recorded in each
determination.
2.10. Statistical analysis
Multiple variances (time and concentration) present in the clo-
nogenic assays were statistically analysed with the two-way
ANOVA model and the Bonferroni’s post hoc test. The results are
represented as the mean ± standard error of the mean (SEM).
Differences with p < 0.05 were considered statistically signiﬁcant.
The analysis was performed with the Graphpad Prism Software.
All other results were statistically analysed with the unpaired
Student’s t test, using the Excel software. The results are
represented as the mean ± SEM. Differences with p < 0.05 were
considered statistically signiﬁcant.
3. Results
3.1. Short-term exposure to Cr(VI) in the low micromolar range had
little impact on the clonogenic potential of BEAS-2B cells
Overtly cytotoxic exposure regimens are of questionable rele-
vance in the context of carcinogenesis. To select an appropriate
regimen for our evaluation of the impact of Cr(VI) on bioenergetics,
we ﬁrst assessed the cytotoxicity of various exposure regimens.
The colony-forming assay was used to this end. As can be seen
(Fig. 1), with the exception of the decreases in clonogenic potential
produced by the highest Cr(VI) concentration tested (2 lM), all
other decreases were rather small and devoid of statistical signiﬁ-
cance. Interestingly, after an initial decrease, the clonogenic poten-
tial of cells exposed to 0.5 lM Cr(VI) increased over time of
exposure. Despite the absence of statistical signiﬁcance, this
increase in clonogenic potential over time for Cr(VI)-exposed cells
is in line with a stimulation of proliferation suggested in two pre-
vious studies by our group with the same cell line and exposure
regimen, but using different endpoints of toxicity (dehydrogenase
activity [10] and trypan blue dye exclusion [15]. Cytotoxicity data
reported by Caglieri and co-workers also suggested a stimulation
of proliferation upon exposure to Cr(VI) in the low micromolar
range [7]. Based on these results, an exposure regimen consisting
of a 48 h exposure to 1 lM Cr(VI) was adopted.
3.2. Cr(VI) compromised the respiratory capacity of BEAS-2B cells
To characterize the impact of the adopted Cr(VI) exposure reg-
imen on cellular respiration, OCRs were determined for control and
Cr(VI)-exposed cells. These determinations were carried out both
under basal conditions and after sequentially exposing cells to four
well-deﬁned modulators of oxidative phosphorylation (OXPHOS):
oligomycin (an inhibitor of the mitochondrial H+-ATP synthase),
2,4-DNP (which uncouples electron transport from ATP synthesis),
rotenone (an inhibitor of complex I of the mitochondrial electron
transport chain (ETC)) and antimycin (an inhibitor of complex III
of the ETC). The real-time proﬁles obtained using the Seahorse
XF24 Extracellular Flux Analyzer can be seen in Fig. 2A. Control
and Cr(VI)-exposed cells responded identically to the three
inhibitors tested, but OCRs were always slightly attenuated in
Fig. 1. Short-term exposure (24–72 h) to Cr(VI) in the low micromolar range had
little or no effect in the colony forming potential of BEAS-2B cells. Values represent
the mean ± SEM of 3 independent experiments. In each experiment, at least
duplicate cultures were prepared for each condition. Multiple comparisons by
analysis of variance were done with two-way ANOVA model and the post hoc
Bonferroni’s test conﬁrmed that there were no signiﬁcant differences (p > 0.05).
Fig. 2. Short-term exposure (48 h) to 1 lM Cr(VI) compromised the respiratory
capacity of BEAS-2B cells. (A) Bioenergetic proﬁles obtained using the XF24
Extracellular Flux Analyzer. The arrows represent the sequential addition of 6 lM
oligomycin (OL), 750 lM 2,4-dinitrophenol (DNP), 1 lM rotenone (ROT) and 1 lM
antimycin (ANT). (B) Oxygen consumption rates under basal and uncoupling
conditions (i.e., after DNP addition) for control and Cr(VI)-exposed cells. Data
represent the mean ± SEM for 8 determinations. Asterisks indicate p < 0.05 (*) or
p < 0.01 (**), when compared with control values by Student’s t test; Cardinals
indicate p < 0.05 (#) when compared with the respective basal value by Student’s t
test.
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an effect also observed under basal conditions. Differences in OCRs
between control and Cr(VI)-exposed cells were much more pro-
nounced under uncoupling conditions, i.e., when dissipation of
the mitochondrial proton gradient maximized mitochondrial res-
piration. As can be appreciated in Fig. 2, while control cells
responded to 2,4-DNP addition by a signiﬁcant upregulation of
mitochondrial respiration (by ca. 40%, compared to basal values),
Cr(VI)-exposed cells exhibited a modest upregulation. Altogether,
the results suggest that Cr(VI) compromised the respiratory capac-
ity of BEAS-2B cells and that respiration of Cr(VI)-exposed cells
under basal conditions was already close to its maximum.
3.3. Cr(VI) augmented the glycolytic capacity of BEAS-2B cells
Next, we assessed the impact of the same Cr(VI) exposure on
aerobic glycolysis, by comparing the rates of lactate production
by Cr(VI)-exposed cells with those of control cells. Determinations
were conducted both under basal conditions and under conditions
that impaired OXPHOS-mediated ATP synthesis (Fig. 3). Basal lac-
tate production rates were slightly higher in Cr(VI)-exposed cells
than in control cells. Oligomycin elicited a small stimulation of lac-
tate production, which was essentially identical in both control
and Cr(VI)-exposed cells. Once again, differences between control
and Cr(VI)-exposed cells became more evident in the presence of
2,4-DNP. In fact, the upregulation of lactate production induced
by this uncoupler in Cr(VI)-exposed cells was much stronger than
that induced in control cells, which suggests an increased glyco-
lytic capacity for Cr(VI)-exposed cells.
3.4. Intracellular ATP levels of BEAS-2B cells remained essentially
unaltered upon Cr(VI) exposure
Intracellular ATP levels in control and Cr(VI)-exposed cells were
determined under basal conditions and under conditions that
impaired glycolytic or OXPHOS-mediated ATP synthesis (Fig. 4).
Despite their attenuated OCRs, Cr(VI)-exposed cells exhibited ATP
levels comparable to those of the corresponding controls underall four experimental conditions tested. The accompanying rise in
aerobic glycolysis described in the previous section might have
contributed to this compensatory mechanism. Inhibition of
OXPHOS by oligomycin provoked a dramatic drop in ATP levels
in both control and Cr(VI)-exposed cells, revealing that fermenta-
tion alone was unable to maintain basal ATP levels. This result indi-
cates that BEAS-2B cells normally regenerate ATP mostly by
electron transfer phosphorylation. An identically dramatic drop
in intracellular ATP levels was observed upon incubation with
2-DG, a competitive inhibitor of hexokinase, the ﬁrst enzyme of
glycolysis. This observation shows that these cells were deriving
most of their energy from the oxidation of glucose, and not from
the oxidation of glutamine, a fuel molecule also present in the
growth medium used. Although substantial, the decrease in intra-
cellular ATP levels observed under uncoupling conditions was
much less pronounced than those observed in the presence of
oligomycin or 2-DG. The ability of 2,4-DNP to strongly upregulate
glycolysis might have contributed to this result.
3.5. Changes in the expression of GAPDH and b-F1-ATPase induced by
Cr(VI) exposure translated into an altered bioenergetic signature
Our investigation into the mechanisms by which Cr(VI) altered
the bioenergetic phenotype of BEAS-2B cells included the evalua-
tion of the effects of this carcinogen on the protein levels of GAPDH
and b-F1ATPase, which can be used as markers of glycolytic and
OXPHOS activity, respectively. These determinations, which were
carried out by Western blot analysis, showed that the levels of
these two proteins were differentially affected by Cr(VI): whereas
Fig. 3. Short-term exposure (48 h) to 1 lM Cr(VI) augmented the glycolytic capacity of BEAS-2B cells under basal and uncoupling conditions. The results shown are the
mean ± SEM of 4 determinations. Asterisks indicate p < 0.05 (*) or p < 0.01 (**), when compared with control values by Student’s t test; Cardinals indicate p < 0.01 (##) or
p < 0.001 (###), when compared with the respective basal value by Student’s t test. OL, oligomycin; DNP, 2,4-dinitrophenol.
Fig. 4. Intracellular ATP levels of BEAS-2B cells remained unaltered upon short-
term exposure (48 h) to 1 lM Cr(VI), under all 4 experimental conditions tested.
Values represent the means ± SEM of 3 independent experiments. Cardinals
indicate p < 0.05 (#), p < 0.01 (##) or p < 0.001 (###), when compared with the
respective basal value by Student’s t test. 2-DG, 2-deoxyglucose; OL, oligomycin;
2,4-DNP, 2,4-dinitrophenol. Fig. 5. Short-term (48 h) exposure to 1 lM Cr(VI) altered the protein levels of
glycolytic (GAPDH) and mitochondrial (b-F1-ATPase) markers. (A) Representative
western blot of the expression of b-F1-ATPase and GAPDH in two different
preparations of control and exposed cells. (B) Values represent the relative
expression (i.e., compared to control cultures; mean ± SEM) of b-F1-ATPase
(n = 14), GAPDH (n = 13) and b-F1-ATPase:GAPDH ratio. Asterisks indicate p < 0.05
(*) or p < 0.001 (***), when compared with control values by Student’s t test. b-F1-
ATPase, catalytic subunit (subunit b) of the mitochondrial H+-ATP synthase; GAPDH,
glyceraldehyde-3-phosphate dehydrogenase.
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were slightly decreased (Fig. 5). As a consequence, the b-F1-ATP-
ase/GAPDH protein ratio, viewed as a cellular bioenergetic signa-
ture [43], was signiﬁcantly diminished in Cr(VI)-exposed cells.
3.6. Oligomycin treatment signiﬁcantly increased levels of oxidative
stress in Cr(VI)-exposed cells
In order to further investigate the mechanisms of Cr(VI)-
induced changes in the bioenergetic phenotype of BEAS-2B cells,
levels of oxidative stress were assessed, by ﬂow cytometry and
using the redox probe DCFH-DA, in control and Cr(VI)-exposed
cells. These determinations were carried out both under basal con-
ditions and in the presence of oligomycin (Fig. 6). Basal levels of
oxidative stress were identical in control and Cr(VI)-exposed cells
(the small increase observed upon Cr(VI) exposure was not statis-
tically signiﬁcant). However, whereas control cells were able to
prevent an increase in oxidative stress when challenged byoligomycin treatment, Cr(VI)-exposed cells were not (Fig. 6B). This
result might indicate a negative impact of Cr(VI) on the cellular
antioxidant defenses.
4. Discussion
In 1990, based on extensive epidemiological, animal and other
relevant studies, the International Agency for Research on Cancer
(IARC) classiﬁed Cr(VI) compounds as encountered in the chromate
production, chromate pigment production and chromium plating
industries as carcinogenic to humans [23]. The observations made
Fig. 6. Short-term (48 h) exposure to Cr(VI) augmented oxidative stress levels in
oligomycin (OL)-treated BEAS-2B cells. Values represent the mean ± SEM of four
determinations. Asterisks indicate p < 0.001 (***), when compared with control
values by Student’s t test; Cardinals indicate p < 0.001 (###) when compared with
the respective basal value by Student’s t test.
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the main targets of Cr(VI) toxicity, to low Cr(VI) concentrations
are in line with this classiﬁcation. These observations included
changes in morphology and pattern of growth characteristic of
an early phase of pre-malignant progression [10] and overexpres-
sion of genes commonly involved in malignant transformation
(e.g.,MYC) [40]. Yet, despite the combined efforts of many research
groups, the molecular basis of Cr(VI) carcinogenicity remains elu-
sive [49]. Namely, clariﬁcation is needed on the impact of Cr(VI)
compounds on mammalian cell bioenergetics. In spite of various
reports on changes in critical bioenergetic parameters induced by
Cr(VI) exposure [1,49], speciﬁc Cr(VI)-induced bioenergetic pheno-
types have not yet been ﬁrmly established. The main aim of the
present study was to produce additional, biologically relevant data
regarding this aspect.
The increased risk of chromate lung cancer is associated with
the inhalation of Cr(VI) particles [5]. These particles adhere to
the surface of bronchial epithelial cells and slowly release, in their
close vicinity, soluble Cr(VI) oxyanions. Some of these ions, present
essentially in the form of chromate, escape extracellular reduction
and readily cross cell membranes [3,45]. Once in the intracellular
milieu, they undergo reduction and various reactive species are
formed that cause cellular damage [33,54].
To address the issue of biological relevance, we employed a cell
line (BEAS-2B) that was derived from normal human bronchial epi-
thelium. Although immortalized through viral infection, BEAS-2B
cells retain features of human bronchial epithelial cells and only
became tumorigenic (very weakly) at passages much higher than
those used in this study [38,39]. In the present study, BEAS-2B cells
were submitted to 1 lM Cr(VI) for 48 h, an exposure regimen that
was not overtly cytotoxic to them, as demonstrated by us in this
and previous studies [10,15], using three different endpoints of
toxicity. Also, according to a study by Caglieri and collaborators,
BEAS-2B cells exposed to this Cr(VI) concentration for both 8 and24 h results exhibited an intracellular Cr content (ca. 50 lg/g of
cells) [7] that compares well with the mean Cr content found by
Tsunetta and co-workers in the peripheral lung tissue of chromate
workers with lung cancer (36.7 lg/g wet weight) [47]. The impact
of the chosen Cr(VI) exposure regimen on the bioenergetic pheno-
type of BEAS-2B cells was assessed in terms of cellular respiration,
aerobic glycolysis and intracellular ATP levels. Determinations
were carried out both under basal conditions and in the presence
of well-deﬁned bioenergetic effectors.
Bioenergetic analysis with the XF24 Extracellular Flux Analyzer
demonstrated that a single insult with 1 lM Cr(VI) compromised
the respiratory capacity of BEAS-2B cells. This effectwas best appre-
ciated under uncoupling conditions, which forced the ETC to oper-
ate at its maximal capacity. Inhibition of respiration occurred
concurrently with a stimulation of aerobic glycolysis. Similar to its
effect on respiration, the effect of Cr(VI) on aerobic glycolysis was
rathermodest under basal conditions or in the presence of oligomy-
cin, but became more pronounced under uncoupling conditions,
which collapsed the mitochondrial membrane potential (Dwm). It
is of note that the stimulation of aerobic glycolysis produced by
the uncoupler was signiﬁcantly higher in Cr(VI)-exposed cells than
in control cells. This observation suggests that Cr(VI) increased the
maximal glycolytic capacity of BEAS-2B cells. Upregulation of aero-
bic glycolysis in response to Cr(VI) had been observed previously by
our group in PC-12 cells (a cancer cell line) exposed for 6 h to 1–
5 lM Cr(VI) [19] and in BEAS-2B cells over a 6-week exposure to
0.1 and 1.0 lM Cr(VI) [15]. In both cases, upregulation of aerobic
glycolysis was accompanied by increases in glucose uptake rates.
The stronger reliance of cancer cells on a less efﬁcient process of
energy production is seemingly paradoxical, as these rapidly prolif-
erating cells likely require more energy than their normal counter-
parts. Thus, the consistency of this bioenergetic phenotype among
cancer cells strongly points to an impaired respiration, as proposed
by Warburg, and/or to the acquisition of selective growth advanta-
ges not directly related to energy production. In spite of much
speculation, these advantages remain essentially undeﬁned. They
might be related, for instance, to the generation of intermediates
and reducing power for biosynthesis and/or to the acidiﬁcation of
the extracellular milieu [8,43]. Active biosynthesis is required to
sustain proliferation and the acidiﬁcation of the extracellular
milieu, which accompanies lactate upregulation, has been shown
to promote, in several model systems, neoangiogenesis, anchor-
age-independent growth, genetic instability, facilitating invasion.
Interestingly, in these model systems, acidiﬁcation occurred early
in transformation [8]. Therefore, it is possible that the shift to a
more fermentative metabolism observed in our study upon
short-term incubation (48 h) of BEAS-2B cells to Cr(VI) constitutes
an early step in Cr(VI)-induced lung cancer.
The ability of both control and Cr(VI)-exposed BEAS-2B cells to
upregulate aerobic glycolysis in response to oligomycin-induced
OXPHOS inhibition was very limited. As a consequence, their intra-
cellular ATP levels decreased dramatically. On the contrary, these
cells were able to more than double their rates of aerobic glycolysis
when stressed with 2,4-DNP. Nonetheless, the upregulation of aer-
obic glycolysis was still insufﬁcient to ensure basal ATP levels. Very
pronounced decreases in ATP levels were also observed in the pres-
ence of 2-DG, which suggests that BEAS-2B cells are not able to use
glutamine, present in the growth medium in levels analogous to
those of glucose, as a major energy source. Lastly, differences in
ATP levels between control and Cr(VI)-exposed cells were very
modest under all four experimental conditions tested (the differ-
ences were never statistically signiﬁcant).
Attenuation of respiration by Cr(VI) has been consistently
reported in the literature, both in cultured cells and in isolated
mitochondria [1]. However, the underlying mechanisms of this
attenuation are poorly understood. It has been speculated that
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citrate) by Cr species might compromise substrate availability to
the ETC [41,42]. It is also possible that processes of ATP generation
are compromised due to the formation of stable coordination com-
plexes between Cr(III) and ATP precursors and/or proteins involved
in these processes [1]. There are, in fact, reports of changes in the
activities of these enzymes upon Cr(VI) exposure, as well as
changes in their intracellular levels and in the expression of the
corresponding genes [1]. However, these changes were heavily
dependent on the model systems employed, preventing the estab-
lishment of reliable trends. It is, nonetheless, worth mentioning
that complex I of the ETC was found inhibited in six out of seven
reported studies, and complex III was found inhibited in ﬁve out
of six [14,17,31,32,34,52,53]. One of these studies assessed also
the effects on aconitase, reporting the inhibition of this tricarbox-
ylic acid (TCA) cycle enzyme [34]. By attenuating the TCA cycle,
aconitase inhibition might slow down the production of NADH,
the source of electrons to complex I, ultimately attenuating
respiration. In fact, ﬂuorocitrate, a speciﬁc inhibitor of aconitase,
inhibited respiration [18].
The immunologic analysis carried out in the present study pro-
vided additional insight into the molecular basis of the observed
Cr(VI)-induced bioenergetic effects. In this analysis, GAPDH and
b-F1-ATPase were used as markers of glycolytic and OXPHOS activ-
ities, respectively. It is of note that b-F1-ATPase, which is the cata-
lytic subunit of the H+-ATP synthase complex, is a rate-limiting
component of OXPHOS. The results obtained are in line with the
impaired respiration and augmented glycolytic potential just dis-
cussed: b-F1-ATPase proteins levels were decreased, whereas those
of GAPDH were increased. Altogether, this dual effect resulted into
a lower b-F1-ATPase/GAPDH protein ratio, similar to what has been
described in common human cancers [2,12,25].
We next investigated the possible involvement of oxidative
stress in the bioenergetic changes induced by Cr(VI) exposure, as
the intracellular reduction of Cr(VI) is accompanied by the genera-
tion of strong oxidants, such as Cr(IV), Cr(V) and ROS [33]. We
observed that the impact of Cr(VI) exposure on oxidative stress lev-
els depended on the experimental conditions. Under basal condi-
tions, these levels remained basically unaltered, indicating that
the antioxidant defense system of BEAS-2B cells was able to cope
with any upregulation of Cr(IV), Cr(V) and/or ROS (the probe used
is not able to discriminate between these species [26]) that the
Cr(VI) exposure regimen adopted might have produced. On the
contrary, levels of oxidative stress were much increased when cells
were also treated with oligomycin. In the presence of this speciﬁc
inhibitor of the ATP synthase, which blocks its proton channel, pro-
tons tend to accumulate in the mitochondrial inter-membrane
space, triggering an increase of Dwm [44]. In turn, increases in
Dwm are associated with ROS formation [22]. Whereas control cells
were able to maintain their levels of oxidative stress when treated
with oligomycin, Cr(VI)-exposed cells did not, exhibiting much
increased levels of oxidative stress in the presence of this inhibitor.
This inability of Cr(VI)-exposed cells to counterbalance the
increased production of ROS likely induced by oligomycin suggests
that Cr(VI) compromises the antioxidant defenses of BEAS-2B cells.
This is in line with previous reports of Cr(VI) interference with
some components of the antioxidant defense system of mamma-
lian cells [1], namely with the thioredoxin system [35,36], which
plays a major role in the maintenance of the intracellular thiol-
disulﬁde redox balance [30].
5. Conclusions
The results obtained in this study provided mechanistic insights
into the metabolic reprogramming of lung cancer cells to anenhanced aerobic glycolysis. Speciﬁcally, our study revealed pro-
teomic changes in Cr(VI)-exposed cells (decreased b-F1-ATPase lev-
els and augmented GAPDH levels) that might have translated into a
lower mitochondrial potential for energy generation and an
increased glycolytic competence. Our results also suggest that
Cr(VI) interferes with the cellular antioxidant system.
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